Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
A phase 3 trial of Namodenoson in hepatocellular carcinoma, run by Can-Fite BioPharma, now recruiting.
Overview
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis is a phase 3 interventional study registered as NCT05201404 by Can-Fite BioPharma, with 471 participants planned, started 2023-03-15 and due to reach its primary completion in 2026-02. Interventions recorded: Namodenoson and Placebo.
Similar pages
not linked directly; found by shared links- TrialNamodenoson Treatment of Advanced Pancreatic Cancer
Shares Can-Fite BioPharma and the tag pipeline.
- TrialA Study of PTX-9908 Injection for Non-resectable HCC with TACE
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialGPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialTo Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialA Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Shares Hepatocellular carcinoma and the tag pipeline.